Stoke Therapeutics
STOK
26.81
-0.12
-0.45%
Stoke Therapeutics
US · STOK
#2942 by market cap
Listed 2019
26.81
-0.12
-0.45%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 6 in the most recent period (2026/Q3).
- Total institutional ownership fell 5.6 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 123.01% -5.58pp
- Institutions
- 237 -6
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund72.57%
Hedge Fund33.86%
Public Company11.15%
VC/PE Fund4.16%
Individual/Insider3.65%
Government Pension Fund0.36%
Private Company0.35%
Insurance Company0.26%
Sovereign Wealth Fund0.25%
Top holders as of 2026-09-30
BlackRock
9.71% · 6.35M sh
RTW Investments, LP
8.60% · 5.62M sh
T. Rowe Price Group, Inc.
7.76% · 5.08M sh
FMR
7.65% · 5.00M sh
Lynx1 Capital Management LP
6.17% · 4.04M sh
Redmile Group, LLC
6.03% · 3.95M sh
BVF Partners L.P.
5.52% · 3.61M sh
Wellington Management Group
5.38% · 3.52M sh
Baker Bros. Advisors LP
5.10% · 3.34M sh
Morgan Stanley
4.91% · 3.21M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 24 buys · 26 sells
| Name | Role | Stake |
|---|---|---|
| Seth Harrison | Independent Director | 2.87% |
| Adrian Krainer | Co-Founder & Independent Director | 0.43% |
| Edward Kaye | Former Advisor & Director | 0.19% |
| Arthur Tzianabos | Chairperson | 0.05% |
| Arthur Levin | Independent Director | 0.03% |
| Jonathan Allan | Corporate Secretary, Compliance Officer & General Counsel | 0.03% |
| Barry Ticho | Chief Medical Officer | 0.02% |
| Jason Hoitt | Chief Patient Officer | 0.02% |
| Thomas Edward Leggett | Chief Financial Officer | 0.02% |
| Ian Smith | Chief Executive Officer | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-01 | Barry Ticho | Chief Medical Officer | Automatic Disposition | -7,195 | $26.38–26.99 |
| 2026-10-01 | Jonathan Allan | Corporate Secretary, Compliance Officer & General Counsel | Automatic Disposition | -627 | $26.33 |
| 2026-09-30 | Barry Ticho | Chief Medical Officer | Automatic Disposition | -1,051 | $26.16 |
| 2026-09-22 | Alexander Cumbo | Director | Other Derivative Acquisition | +39,674 | $26.11 |
| 2026-08-31 | Barry Ticho | Chief Medical Officer | Automatic Disposition | -5,545 | $30.51–31.06 |
| 2026-08-17 | Edward Kaye | Former Advisor & Director | Derivative Exercise and Sale | -12,567 | $32.01–32.47 |
| 2026-08-17 | Barry Ticho | Chief Medical Officer | Derivative Exercise and Sale | -4,767 | $32.01–32.47 |
| 2026-08-17 | Jonathan Allan | Corporate Secretary, Compliance Officer & General Counsel | Derivative Exercise and Sale | -2,861 | $32.01–32.47 |
| 2026-08-13 | Edward Kaye | Former Advisor & Director | Derivative Exercise and Retained | +13,683 | -- |
| 2026-08-13 | Barry Ticho | Chief Medical Officer | Derivative Exercise and Retained | +5,233 | -- |
| 2026-08-13 | Jonathan Allan | Corporate Secretary, Compliance Officer & General Counsel | Derivative Exercise and Retained | +3,139 | -- |
| 2026-08-02 | Barry Ticho | Chief Medical Officer | Automatic Disposition | -7,176 | $28.95–29.45 |
| 2026-07-15 | Seth Harrison | Independent Director | Other Derivative Acquisition | +151,595 | $10.90–40.37 |
| 2026-07-15 | Seth Harrison | Independent Director | Other Derivative Disposition | -151,595 | $10.90–40.37 |
| 2026-07-14 | Thomas McCauley | Chief Scientific Officer | Other Derivative Acquisition | +225,000 | $29.91 |
| 2026-06-30 | Barry Ticho | Chief Medical Officer | Automatic Disposition | -7,228 | $32.62–33.27 |
| 2026-06-15 | Jonathan Allan | Corporate Secretary, Compliance Officer & General Counsel | Automatic Disposition | -1,457 | $29.95 |
| 2026-06-02 | Seth Harrison | Independent Director | Other Derivative Acquisition | +17,786 | $29.46 |
| 2026-06-02 | Arthur Levin | Independent Director | Other Derivative Acquisition | +17,786 | $29.46 |
| 2026-06-02 | Julie Smith | Independent Director | Other Derivative Acquisition | +17,786 | $29.46 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Stoke Therapeutics discussion 0 comments